Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel R Payer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Leukemia & Lymphoma|December 30, 2009
Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio valuesIñigo Santamaría, Angel R Payer, Ana S Pitiot, et al.
Biomed Research International|October 15, 2014
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cellsAndrea Acebes-Huerta, Leticia Huergo-Zapico, Ana Pilar Gonzalez-Rodriguez, et al.
Biomed Research International|October 29, 2013
Lenalidomide and chronic lymphocytic leukemiaAna Pilar González-Rodríguez, Angel R Payer, Andrea Acebes-Huerta, et al.
Oncoimmunology|November 11, 2017
Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemiaMónica Villa-Álvarez, Seila Lorenzo-Herrero, Ana P Gonzalez-Rodriguez, et al.
Frontiers in Immunology|January 9, 2019
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic LeukemiaMónica Villa-Álvarez, Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, et al.
Plos One|October 7, 2014
Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive diseaseLeticia Huergo-Zapico, Andrea Acebes-Huerta, Ana Pilar Gonzalez-Rodriguez, et al.
Journal of Clinical Medicine|November 20, 2020
Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive ProgressionAna P Gonzalez-Rodriguez, Angel R Payer, Juan J Menendez-Suarez, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Haematologica|July 6, 2014
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruptionJulio Delgado, Itziar Salaverria, Tycho Baumann, et al.
Blood|May 1, 2014
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcomeAlejandra Martínez-Trillos, Magda Pinyol, Alba Navarro, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|December 30, 2009
Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio valuesIñigo Santamaría, Angel R Payer, Ana S Pitiot, et al.
Biomed Research International|October 15, 2014
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cellsAndrea Acebes-Huerta, Leticia Huergo-Zapico, Ana Pilar Gonzalez-Rodriguez, et al.
Biomed Research International|October 29, 2013
Lenalidomide and chronic lymphocytic leukemiaAna Pilar González-Rodríguez, Angel R Payer, Andrea Acebes-Huerta, et al.
Oncoimmunology|November 11, 2017
Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemiaMónica Villa-Álvarez, Seila Lorenzo-Herrero, Ana P Gonzalez-Rodriguez, et al.
Frontiers in Immunology|January 9, 2019
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic LeukemiaMónica Villa-Álvarez, Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, et al.
Plos One|October 7, 2014
Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive diseaseLeticia Huergo-Zapico, Andrea Acebes-Huerta, Ana Pilar Gonzalez-Rodriguez, et al.
Journal of Clinical Medicine|November 20, 2020
Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive ProgressionAna P Gonzalez-Rodriguez, Angel R Payer, Juan J Menendez-Suarez, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Haematologica|July 6, 2014
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruptionJulio Delgado, Itziar Salaverria, Tycho Baumann, et al.
Blood|May 1, 2014
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcomeAlejandra Martínez-Trillos, Magda Pinyol, Alba Navarro, et al.
Pageof 2